| 000 | 01480 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516081538.0 | ||
| 264 | 0 | _c20120508 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1038/clpt.2011.269 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiu, Y | |
| 245 | 0 | 0 |
_aDecreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cApr 2012 |
||
| 300 |
_a660-5 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBlack or African American _xgenetics |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGenetic Variation _xgenetics |
| 650 | 0 | 4 | _aHep G2 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetabolic Clearance Rate _xgenetics |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolymorphism, Genetic _xgenetics |
| 650 | 0 | 4 |
_aWarfarin _xpharmacokinetics |
| 700 | 1 | _aJeong, H | |
| 700 | 1 | _aTakahashi, H | |
| 700 | 1 | _aDrozda, K | |
| 700 | 1 | _aPatel, S R | |
| 700 | 1 | _aShapiro, N L | |
| 700 | 1 | _aNutescu, E A | |
| 700 | 1 | _aCavallari, L H | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 91 _gno. 4 _gp. 660-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/clpt.2011.269 _zAvailable from publisher's website |
| 999 |
_c21585551 _d21585551 |
||